References
1. Tringale KR, Marshall D, Mackey TK, Connor M, Murphy JD,
Hattangadi-Gluth JA. Types and Distribution of Payments From Industry to
Physicians in 2015. JAMA. 2017;317(17):1774-84.
2. Marshall DC, Tarras ES, Rosenzweig K, Korenstein D, Chimonas S.
Trends in Industry Payments to Physicians in the United States From 2014
to 2018. JAMA. 2020;324(17):1785-8.
3. Institute of Medicine. Conflict of Interest in Medical Research,
Education, and Practice. Lo B, Field MJ, editors. Washington, DC: The
National Academies Press; 2009. 436 p.
4. Ozaki A, Saito H, Senoo Y, Sawano T, Shimada Y, Kobashi Y, et al.
Overview and transparency of non-research payments to healthcare
organizations and healthcare professionals from pharmaceutical companies
in Japan: Analysis of payment data in 2016. Health Policy.
2020;124(7):727-35.
5. Murayama A, Saito H, Tanimoto T, Ozaki A. Financial conflicts of
interest between pharmaceutical companies and executive board members of
internal medicine subspecialty societies in Japan between 2016 and 2020.
J Eval Clin Pract. 2023;29(6):883-6.
6. Murayama A, Mamada H, Shigeta H, Yoshinaga T, Saito H, Yamashita E,
et al. Financial Relationships Between Pharmaceutical Companies and
Rheumatologists in Japan Between 2016 and 2019. J Clin Rheumatol.
2023;29(3):118-25.
7. Murayama A, Kamamoto S, Saito H, Ozaki A. Pharmaceutical payments to
Japanese board-certified dermatologists: a 4-year retrospective analysis
of personal payments from pharmaceutical companies between 2016 and
2019. Sci Rep. 2023;13(1):7425.
8. Murayama A, Kamamoto S, Kawashima M, Saito H, Yamashita E, Tanimoto
T, Ozaki A. Cross-sectional analysis of pharmaceutical payments to
Japanese board-certified gastroenterologists between 2016 and 2019. BMJ
Open. 2023;13(4):e068237.
9. Murayama A, Kamamoto S, Saito H, Yamada K, Bhandari D, Shoji I, et
al. Pharmaceutical Payments to Japanese Board-Certified Infectious
Disease Specialists: A Four-Year Retrospective Analysis of Payments from
92 Pharmaceutical Companies between 2016 and 2019. Int J Environ Res
Public Health. 2022;19(12):7417.
10. Murayama A, Hoshi M, Saito H, Kamamoto S, Tanaka M, Kawashima M, et
al. Nature and Trends in Personal Payments Made to the Respiratory
Physicians by Pharmaceutical Companies in Japan between 2016 and 2019.
Respiration. 2022;101(12):1088-98.
11. Murayama A, Kamamoto S, Murata N, Yamasaki R, Yamada K, Yamashita E,
et al. Evaluation of financial conflicts of interest and quality of
evidence in Japanese gastroenterology clinical practice guidelines. J
Gastroenterol Hepatol. 2023;38(4):565-73.
12. Kamamoto S, Murayama A, Kusumi E, Yoshida M, Saito H, Sawano T, et
al. Evaluation of financial relationships between Japanese certified
pediatric hematologist/oncologists and pharmaceutical companies: a
cross-sectional analysis of personal payments from pharmaceutical
companies between 2016 and 2019. Pediatr Blood Cancer.
2022;69(10):e29891.
13. Murayama A, Kugo H, Saito Y, Saito H, Tanimoto T, Ozaki A. A 9-Year
Investigation of Healthcare Industry Payments to Pulmonologists in the
United States. Ann Am Thorac Soc. 2023;20(9):1283-92.
14. Murayama A, Nakano K, Kamamoto S, Sato M, Saito H, Tanimoto T, Ozaki
A. Trend in industry payments to infectious disease physicians in the
United States: a seven-year analysis of nonresearch payments from the
Open Payments Database between 2014 and 2020. Clin Microbiol Infect.
2022;28(12):1655 e1- e4.
15. Murayama A, Kamamoto S, Higuchi K, Shigeta H, Ozaki A. Trend in
Industry Payments to Rheumatologists in the United States During the
COVID-19 Pandemic Between 2013 and 2021. J Rheumatol. 2023;50(4):575-7.
16. Inoue K, Blumenthal DM, Elashoff D, Tsugawa Y. Association between
physician characteristics and payments from industry in 2015-2017:
observational study. BMJ Open. 2019;9(9):e031010.
17. Clinckemaillie M, Scanff A, Naudet F, Barbaroux A. Sunshine on KOLs:
assessment of the nature, extent and evolution of financial ties between
the leaders of professional medical associations and the pharmaceutical
industry in France from 2014 to 2019: a retrospective study. BMJ Open.
2022;12(2):e051042.
18. Karanges EA, Ting N, Parker L, Fabbri A, Bero L. Pharmaceutical
industry payments to leaders of professional medical associations in
Australia: Focus on cardiovascular disease and diabetes. Aust J Gen
Pract. 2020;49(3):151-4.
19. Pokorny AMJ, Bero LA, Moynihan R, Mintzes BJ. Industry payments to
Australian medical oncologists and clinical haematologists: a
cross-sectional analysis of publicly available disclosures. Intern Med
J. 2021;51(11):1816-24.
20. Murayama A, Kamamoto S, Saito H, Tanimoto T, Ozaki A. Industry
payments to allergists and clinical immunologists in the United States
during the coronavirus disease 2019 pandemic. Ann Allergy Asthma
Immunol. 2022;129(5):635-6.
21. Murayama A. Industry-sponsored research funding to allergists and
clinical immunologists in the United States. Ann Allergy Asthma Immunol.
2023;131(3):395-7.
22. Japanese Society of Allergology. List of board-certified allergy
specialists and advisors Online: Japanese Society of Allergology; 2022
[Available from:https://www.jsaweb.jp/modules/specialist/index.php?content_id=6.
23. Japan Pharmaceutical Manufacturers Association. Regarding the
Transparency Guideline for the Relation between Corporate Activities and
Medical Institutions 2018 [Available from:https://www.jpma.or.jp/english/code/transparency_guideline/eki4g60000003klk-att/transparency_gl_intro_2018.pdf.
24. Murayama A, Kamamoto S, Saito H, Yamashita E, Suzuki Y, Tanimoto T,
et al. Characteristics and Distribution of Scholarship Donations From
Pharmaceutical Companies to Japanese Healthcare Institutions in 2017: A
Cross-sectional Analysis. International Journal of Health Policy and
Management. 2023;12.
25. Murayama A, Kamamoto S, Kugo H, Saito H, Ozaki A. Research and
Nonresearch Industry Payments to Nephrologists in the United States
between 2014 and 2021. J Am Soc Nephrol. 2023;34(10):1709-20.
26. Murayama A. Nine-Year Analysis of Industry Payments to Geriatricians
in the United States Between 2014 and 2022. J Am Med Dir Assoc. 2023.
27. Murayama A. A nine-year investigation of industry research and
non-research payments to emergency physicians in the United States
between 2014 and 2022. The Journal of Emergency Medicine. 2023.
28. Murayama A, Shigeta H, Kamamoto S, Yamashita E, Saito H, Sawano T,
et al. Pharmaceutical Payments to Japanese Board-Certified Head and Neck
Surgeons Between 2016 and 2019. OTO Open. 2023;7(1):e31.
29. Murayama A, Saito H, Kamamoto S, Shigeta H, Yamashita E, Tanimoto T,
Ozaki A. Evaluation of non-research payments from pharmaceutical
companies to urologists in Japan between 2016 and 2019. Int Urogynecol
J. 2023;34(6):1285-92.
30. Kobashi Y, Kawamura T, Shimazu Y, Zhao T, Sugiyama A, Nakayama A, et
al. Humoral immunity after second dose of BNT162b2 vaccine in Japanese
communities: an observational cross-sectional study, Fukushima
Vaccination Community Survey. Sci Rep. 2022;12(1):18929.
31. Kusumi E, Murayama A, Kamamoto S, Kawashima M, Yoshida M, Saito H,
et al. Pharmaceutical payments to Japanese certified hematologists: a
retrospective analysis of personal payments from pharmaceutical
companies between 2016 and 2019. Blood Cancer J. 2022;12(4):54.
32. Ozieranski P, Csanadi M, Rickard E, Tchilingirian J, Mulinari S.
Analysis of Pharmaceutical Industry Payments to UK Health Care
Organizations in 2015. JAMA Netw Open. 2019;2(6):e196253.
33. Mamada H, Murayama A, Kamamoto S, Kaneda Y, Yoshida M, Sugiura S, et
al. Evaluation of Financial and Nonfinancial Conflicts of Interest and
Quality of Evidence Underlying Psoriatic Arthritis Clinical Practice
Guidelines: Analysis of Personal Payments From Pharmaceutical Companies
and Authors’ Self-Citation Rate in Japan and the United States.
Arthritis Care Res (Hoboken). 2023;75(6):1278-86.
34. Murayama A, Kamamoto S, Shigeta H, Ozaki A. Industry Payments During
the COVID-19 Pandemic to Cardiologists in the United States. CJC Open.
2023;5(3):253-5.
35. Murayama A, Kamamoto S, Saito H, Tanimoto T, Ozaki A. Trends in
Industry Payments to Diabetologists and Endocrinologists in the United
States During the COVID-19 Pandemic. Cureus. 2022;14(12):e32643.
36. Murayama A. Evaluation of Research and Non-research Industry
Payments to Endocrinologists in the United States: An Analysis of the
Open Payments Database from 2014 to 2022. Diabet Med. 2023:e15253.
37. Kamamoto S, Ozaki A, Murayama A. Assessment of Financial
Relationships Between Otorhinolaryngologists and Pharmaceutical
Companies in Japan Between 2016 and 2019. Cureus. 2023;15(8):e43633.
38. Matubara A, Sakashita M, Goto Y, Kawashima K, Matsuoka T, Kondo S,
et al. [National epidemiological survey of nasal allergy 2019 (1998,
compared with 2008): preliminary report - otolaryngologists and their
families]. J Otolaryngol Jpn. 2020;123(6):485–90.
39. Meltzer EO, Blaiss MS, Derebery MJ, Mahr TA, Gordon BR, Sheth KK, et
al. Burden of allergic rhinitis: results from the Pediatric Allergies in
America survey. J Allergy Clin Immunol. 2009;124(3 Suppl):S43-70.
40. Wheatley LM, Togias A. Clinical practice. Allergic rhinitis. N Engl
J Med. 2015;372(5):456-63.
41. Salo PM, Calatroni A, Gergen PJ, Hoppin JA, Sever ML, Jaramillo R,
et al. Allergy-related outcomes in relation to serum IgE: results from
the National Health and Nutrition Examination Survey 2005-2006. J
Allergy Clin Immunol. 2011;127(5):1226-35.e7.
42. Du W, Maekawa Y, Natsui K. [Developmental history of sublingual
immunotherapy]. Nihon Yakurigaku Zasshi. 2019;154(1):6-11.
43. Scher JU, Schett G. Key opinion leaders - a critical perspective.
Nat Rev Rheumatol. 2021;17(2):119-24.
44. Moynihan R. Key opinion leaders: independent experts or drug
representatives in disguise? BMJ. 2008;336(7658):1402-3.
45. Sismondo S. Key opinion leaders and the corruption of medical
knowledge: what the Sunshine Act will and won’t cast light on. J Law Med
Ethics. 2013;41(3):635-43.
46. Moynihan R, Albarqouni L, Nangla C, Dunn AG, Lexchin J, Bero L.
Financial ties between leaders of influential US professional medical
associations and industry: cross sectional study. BMJ. 2020;369:m1505.
47. Nguyen D-D, Murad L, Nguyen AX-L, Zorigtbaatar A, Bouhadana D,
Deyirmendjian C, et al. Industry Payments to American Editorial Board
Members of Major Urology Journals. European Urology. 2023.
48. Haque W, Alvarenga M, Hsiehchen D. Nonresearch Pharmaceutical
Industry Payments to Oncology Physician Editors. The Oncologist.
2020;25(6):e986-e9.
49. Liu JJ, Bell CM, Matelski JJ, Detsky AS, Cram P. Payments by US
pharmaceutical and medical device manufacturers to US medical journal
editors: retrospective observational study. BMJ. 2017;359:j4619.
50. Murayama A, Kamamoto S, Shigeta H, Saito H, Yamashita E, Tanimoto T,
Akihiko O. Undisclosed financial conflicts of interest with
pharmaceutical companies among the authors of the Esophageal Cancer
Practice Guidelines 2017 by the Japan Esophageal Society. Dis Esophagus.
2022;35(10).
51. Murayama A, Kida F, Ozaki A, Saito H, Sawano T, Tanimoto T.
Financial and Intellectual Conflicts of Interest Among Japanese Clinical
Practice Guidelines Authors for Allergic Rhinitis. Otolaryngol Head Neck
Surg. 2022;166(5):869-76.
52. Tabatabavakili S, Khan R, Scaffidi MA, Gimpaya N, Lightfoot D,
Grover SC. Financial Conflicts of Interest in Clinical Practice
Guidelines: A Systematic Review. Mayo Clin Proc Innov Qual Outcomes.
2021;5(2):466-75.
53. Kida F, Murayama A, Saito H, Ozaki A, Shimada Y, Tanimoto T.
Pharmaceutical company payments to authors of the Japanese Clinical
Practice Guidelines for Hepatitis C treatment. Liver Int.
2021;41(3):464-9.
54. Harada K, Ozaki A, Saito H, Sawano T, Yamamoto K, Murayama A, et al.
Financial payments made by pharmaceutical companies to the authors of
Japanese hematology clinical practice guidelines between 2016 and 2017.
Health Policy. 2021;125(3):320-6.
55. Mamada H, Murayama A, Ozaki A, Hashimoto T, Saito H, Sawano T, et
al. Observational study of financial and non-financial conflicts of
interest among the Japanese government advisory board members concerning
coronavirus disease 2019. Medicine (Baltimore). 2023;102(4):e32776.
56. Thacker PD. Covid-19: How independent were the US and British
vaccine advisory committees? BMJ. 2021;373:n1283.
57. Arthur W, Austin J, Wayant C, Vassar M. Association of Conflicts of
Interest for Public Speakers for the Peripheral and Central Nervous
System Drugs Advisory Committee of the US Food and Drug Administration
With Their Statements. JAMA Neurology. 2019;76(3):368-9.
58. Abola MV, Prasad V. Characteristics and Conflicts of Public Speakers
at Meetings of the Oncologic Drugs Advisory Committee to the US Food and
Drug Administration. JAMA Internal Medicine. 2016;176(3):389-91.
59. Hayes MJ, Prasad V. Financial Conflicts of Interest at FDA Drug
Advisory Committee Meetings. Hastings Cent Rep. 2018;48(2):10-3.
60. Institute of Medicine. Clinical Practice Guidelines We Can Trust.
Graham R, Mancher M, Wolman DM, Greenfield S, Steinberg E, editors.
Washington, DC: The National Academies Press; 2011. 290 p.
61. Nejstgaard CH, Bero L, Hrobjartsson A, Jorgensen AW, Jorgensen KJ,
Le M, Lundh A. Association between conflicts of interest and favourable
recommendations in clinical guidelines, advisory committee reports,
opinion pieces, and narrative reviews: systematic review. BMJ.
2020;371:m4234.
62. Santamaria-Barria JA, Nelson H, Jiang H, Dougherty CE, Jadhav S,
Watanabe-Galloway S, et al. Open Payments Data Analysis of General and
Fellowship-trained Surgeons Receiving Industry General Payments from
2016 to 2020: Payment Disparities and COVID-19 Pandemic Impact. Ann
Surg. 2023.
63. Khunte M, Zhong A, Khunte A, Sanelli P, Forman H, Gandhi D, Malhotra
A. Industry Payments to Radiologists During the Last 5 Years and Impact
of COVID-19 Pandemic. J Am Coll Radiol. 2023;20(6):597-604.
64. Inoue K, Figueroa JF, Kondo N, Tsugawa Y. Changes in industry
marketing payments to physicians during the covid-19 pandemic: quasi
experimental, difference-in-difference study. BMJ Medicine.
2022;1(1):e000219.
65. Murayama A, Kamamoto S, Saito H, Tanimoto T, Ozaki A. The Trend in
Industry Payments During the COVID-19 Pandemic Among Gastroenterologists
and Hepatologists in the United States. Cureus. 2022;14(12):e32711.
66. Murayama A, Hirota S. Industry payments to pathologists in the USA
between 2013 and 2021. J Clin Pathol. 2023;76(8):566-70.
67. Murayama A. Industry-sponsored research funding to infectious
disease physicians in the United States between 2013 and 2021. Clin
Microbiol Infect. 2023;29(10):1348-50.
68. Murayama A. Industry-Sponsored Research Funding to Rheumatologists
in the United States Between 2014 and 2022. J Rheumatol. 2023.
69. Murayama A. Pharmaceutical industry-sponsored meals and
prescriptions of biologics for asthma. J Allergy Clin Immunol Pract.
2023;11(9):2916-8.
70. Murayama A. Industry-sponsored meal payments are associated with
prescriptions and Medicare expenditures on brand-name colchicine in the
United States. International Journal of Rheumatic Diseases.
2023;n/a(n/a).
71. Inoue K, Figueroa JF, DeJong C, Tsugawa Y, Orav EJ, Shen C, Kazi DS.
Association Between Industry Marketing Payments and Prescriptions for
PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the
United States. Circulation: Cardiovascular Quality and Outcomes.
2021;14(5):e007521.
72. Inoue K, Tsugawa Y, Mangione CM, Duru OK. Association between
industry payments and prescriptions of long-acting insulin: An
observational study with propensity score matching. PLOS Medicine.
2021;18(6):e1003645.
73. Duarte-Garcia A, Crowson CS, McCoy RG, Herrin J, Lam V, Putman MS,
et al. Association Between Payments by Pharmaceutical Manufacturers and
Prescribing Behavior in Rheumatology. Mayo Clin Proc. 2022;97(2):250-60.
74. Mitchell AP, Trivedi NU, Gennarelli RL, Chimonas S, Tabatabai SM,
Goldberg J, et al. Are Financial Payments From the Pharmaceutical
Industry Associated With Physician Prescribing? : A Systematic Review.
Ann Intern Med. 2021;174(3):353-61.
75. Mitchell AP, Dusetzina SB, Mishra Meza A, Trivedi NU, Bach PB, Winn
AN. Pharmaceutical industry payments and delivery of non-recommended and
low value cancer drugs: population based cohort study. Bmj.
2023;383:e075512.
76. Japan Pharmaceutical Manufacturers Association. Data Book 2023 2023
[Available from:https://www.jpma.or.jp/news_room/issue/databook/en/rfcmr00000000an3-att/DATABOOK2023_en.pdf.
Table 1. Summary of non-research payments to board-certified allergists